Parkinson's affects more than 1 million people in the US. Only 10 to 20% of people with Parkinson's experience symptoms ...
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
The new Ochsner site will contribute to uncovering additional genes as well as examine health disparities and care access for ...
we could identify individuals with specific deficiencies and administer oral riboflavin and biotin supplements to those with ...
Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...
Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...
But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for ...
A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback